Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Primer for advisory panels

This article was originally published in The Tan Sheet

Executive Summary

CHPA's Scientific Affairs Committee is looking into ways to help improve the advisory committee review process. The SAC is working on "a document that sort of takes...frequently asked questions, and lays out some of the basics as a primer for advisory committee members," according to Committee Chair Ed Hemwall (J&J/Merck Consumer Pharmaceuticals). SAC would seek FDA endorsement of the document and would then provide it to advisory panel members prior to meetings. The document has not yet been drafted, but its purpose would be to "make sure that committee members understand going into the room the fundamentals of OTC study," such as consumer behavior trials and advertising regulation, Hemwall said. The information would "perhaps help reduce some of the off-topic debate and uninformed speculation that often occurs at these meetings," he added...

You may also be interested in...



From Availability To Awareness: 2007 Brings Wide Range Of Goals For CHPA

The Consumer Healthcare Products Association looks to focus its efforts in 2007 on issues such as Rx-to-OTC switches, rising health care costs, consumer education and prevention of OTC abuse. CHPA President Linda Suydam recently spoke with "The Tan Sheet" about the association's accomplishments during 2006 and goals for the coming year

Robust Trial Transparency Strategy Boosts Patient Engagement

Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.

Medtronic’s Perfusion System Recall Is Fifth Class I In 2 Months

The Bio-Console 560 extracorporeal blood pumping console is being recalled over reports it could lose power during bypass surgery, which could lead to organ or neural dysfunction, blood clots, or even death.

Topics

UsernamePublicRestriction

Register

PS099353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel